オキサセフェム系抗生物質の開発研究
スポンサーリンク
概要
- 論文の詳細を見る
A pioneering work in the field of oxacephem antibiotics which had been carried out in our research laboratories is reviewed. Our research of β-lactam antibiotics was started in 1974 with the policy to make chemical modification at the nuclei but not the side chain of the existing β-lactam antibiotics, with an expectation to discover a new type of antibiotics. After the success in establishing an efficient synthetic method for 3'-nor-cephalosporin, we started oxacephem research in 1975. We succeeded in developing three synthetic methods starting from penicillins which efficiently served to prepare numerous oxacephem (1-oxa-1-dethia-cephalosporin) derivatives. It turned out that the oxacephem nucleus was much more distorted with an increased ring strain, resulting in reduction of the β-lactam amide resonance to a greater extent than the cephalosporin nucleus. This physicochemical properties conferred an increased chemical reactivity on the nucleus as evidenced by an increased hydrolysis rate as compared with the corresponding 1-thia counterpart. This increased chemical reactivity coupled with the reduced hydrophobicity of the oxacephem nucleus as evidenced by the lower distribution constant in a water-octanol system, characterized unique biological properties of oxacephem derivatives. These include (1) 2-16 times increase in antibacterial activity with emphasis against gram-negative bacteria ; (2) increased protecting effect in vivo parallel to the increased in vitro activity ; (3) reduction of the stability to β-lactamases leading to decreased antibacterial activity against the β-lactamase producing strains ; (4) 1.6-3.2 times increase in penetrability through the outer membrane of certain gram-negative bacteria, the increase being due to the increased hydrophilicity of the oxacephem nucleus ; (5) remarkably reduced binding to human serum albumin improving the efficacy of the oxacephems in the blood ; (6) a remarkable change in the excretion pattern, i.e. recovery in the bile reduced and that in the urine increased. These biological characteristics are generally favorable for antibacterial agents against pathogenic diseases except for the reduced stability to β-lactamases. This unfavorable property of the oxacephem nucleus was the only barrier for developing a new agent of the oxacephem nucleus. However, this problem was relatively easily solved by introduction of (1) the methoxy group at 7α and (2) appropriately α-substituted acyl amide side chain at 7β ; the former and the latter substituent effectively stabilized the oxacephems to various kinds of penicillinases and cephalosporinases, respectively. It turned out that both effects were complementary and, thus, combination of both substituents produced perfect stabilization of the oxacephems to β-lactamases, and brought about the complete recovery of the activity against resistant strains. Extensive studies were performed to obtain deep and broad knowledge in structureactivity relationships in the field of the newly explored oxacephems. As the results of these efforts we succeeded in obtaining two important and useful oxacephem compounds, i.e. latamoxef 18 and flomoxef 19. Latamoxef 18 is a very potent and broadly active third generation β-lactam antibiotic, and perfectly stable to various kinds of β-lactamases showing efficacy against most of the resistant bacteria. Moreover, it has very favorable pharmacological properties, such as a high blood level and a long half-life, which are essential for efficacy in human body. One of the drawback of this antibiotic, as commonly observed in the third generation antibiotics, was the rather weak activity against grampositive bacteria, especially against Staphylococcus aureus. This weak point was basically improved by introducing a new 7β-acylamido side chain and by a minor structural change in the N-methyl-tetrazol part, as seen in structure 19. Flomoxef can be characterized by its potent activity against S. aureus with ke
- 社団法人日本薬学会の論文
- 1991-02-25
著者
-
吉田 正
塩野義製薬研究所
-
吉田 正
Shionogi Research Laboratories Shionogi & Co. Ltd.
-
永田 亘
塩野義製薬株式会社研究所
-
永田 亘
塩野義製薬(株)
-
成定 昌幸
塩野義製薬株式会社研究所
-
吉岡 美鶴
塩野義製薬株式会社研究所
-
尾上 弘
塩野義製薬株式会社研究所
-
吉田 正
塩野義製薬株式会社研究所
-
吉田 正
塩野義製薬(株)医薬研究開発部
-
成定 昌幸
塩野義製薬(株)研究所化学研究部
-
吉岡 美鶴
塩野義製薬(株)製造本部
-
成定 昌幸
塩野義製薬 (株) 研究所
-
永田 亘
塩野義製薬 (株) 研究所
関連論文
- Synthesis of 17-Hydroxyimino Steroids and their O-Alkyl Derivatives
- 6. dl-ジベレリンA_の生理活性
- 第2回 日米バンコマイシン・フォーラム
- オキサセフェム系抗生物質の開発研究
- Studies of Antitumor-Active 5-Fluorouracil Derivatives. I. Synthesis of N-Phthalidyl 5-Fluorouracil Derivatives
- 1-オキサセフェム誘導体の合成と抗菌活性 (「医薬品開発をめぐる生理活性物質の合成」特集号)
- 63 分子内閉環による7α-メトキシ-1-オキサセフェム骨格の新しい立体制御的合成
- 新しい骨核を有する合成β-ラクタム抗生物質 (新しい抗生物質の開発と合成)
- Synthetic Studies on Isoquinoline Alkaloids. I. An Efficient Synthesis of 9,10-Substituted Protoberberine Alkaloids
- Synthesis of Bridged Steroids. VII. B-Norsteroids having a Gibbane B-C-D Ring System. (2). Synthesis of the 7-Deoxygibberellin Type Ring System
- Synthesis of Bridged Steroids. VI. B-Norsteroids having a Gibbane B-C-D Ring System. (1). Synthesis of 5-Cyano-B-norsteroids via Hydrocyanation
- 39 dl-ジベレリンA_の立体選択的全合成に於る問題点
- 37 C_ジベレリン類の全合成的研究
- Synthesis of Bridged Steroids. III. Cholestane Derivatives having a Bridged Bicyclo [2. 2. 2] octane Ring System of the Atisine Type
- Synthesis of Bridged Steroids. II. Steroids having a Bridged Bicyclo [3. 2. 1] octane Ring System of the Kaurene Type
- Synthesis of Bridged Steroids. I. Steroids having a Bridged Bicyclo [3. 2. 1] octane Ring System of the Phyllocladene Type
- Nuclear Magnetic Resonance Spectroscopic Evidence for Distorted Conformations of the C-Rings in 8β, 11β- and 11β, 13β-Bridged Steroids
- 28.新hydrocyanation法とそのステロイド合成への応用
- 医薬化学部会の設立について
- 日本化学療法学会抗菌薬感受性測定法検討委員会報告(1996年)尿路感染症における抗菌薬のブレイクポインイ(案)
- Oxacephem系抗生物質6059-Sのグラム陰性菌由来β-lactamaseに対する安定性とその抗菌活性に及ぼす影響 (6059-S)
- Oxacephem系抗生物質6059-Sのin vitro抗菌作用 (6059-S)
- Cefaclorの動物における吸収・排泄・代謝 (Cefaclor(CCL))
- Cefaclorのin vitro抗菌作用 (Cefaclor(CCL))
- Cefamandoleの動物における体内動態 (Cefamandole)
- Cefamandoleのin vitro抗菌作用 (Cefamandole)
- 体液内Tobramycinの微生物学的微量定量法に関する検討 (Tobramycin論文特集号)
- Carbapenem and Penem Antibiotics. VII. Synthesis and Antibacterial Activity of 1β-Methyl-2-(Quaternary Heteroaromatic-thiomethyl) Carbapenems
- 有機合成化学 : その現代的意義
- Carbapenem and Penem Antibiotics. IV. Synthesis and Antibacterial Activity of (5R^*, 6S^*)-6-[(R^*)-1-Hydroxyethyl]-2-functionalized-methyl Carbapenem and Penem Derivatives
- 5α-Pregnan-3β-ol-20-one及びLatifoline,Conessineの全合成
- 名誉会員 William G. Dauben教授を偲んで
- 1-オキサセフェム化合物の合成研究
- 過酸化ニッケルによる酸化反応(第9報)アルデヒドのAmmonoxidationによる酸アミドの合成
- Carbapenem and Penem Antibiotics. III. Synthesis and Antibacterial Activity of 2-Functionalized-methyl Penems Related to Asparenomycins
- Carbapenem and Penem Antibiotics. VI. Synthesis and Antibacterial Activity of 2-Heteroaromatic-thiomethyl and 2-Carbamoyloxymethyl 1-Methylcarbapenems
- Carbapenem and Penem Antibiotics. V. Synthesis and Antibacterial Activity of 2-Functionalized-methyl 1-Methylcarbapenems Related to Asparenomycins
- Carbapenem and Penem Antibiotics. II. Synthesis and Antibacterial Activity of 2-Functionalized-methyl Carbapenems Related to Asparenomycins
- Oxacephem系抗生物質6059-Sの各種動物における体内動態 (6059-S)
- 6059-Sの微生物学的定量法による体液内濃度測定法に関する検討 (6059-S)
- ヒドロシアン化反応 (新しい有機合成反応--その発想と展開)
- ホウ素,アルミニウム (金属の特性を活かした新しい有機合成反応)
- Synthesis and Structure-Activity Relationships of 7-(3'-Amino-4'-methoxypyrolidin-1'-yl)-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic Acids
- RNAワールド形成仮説 : 合成化学者の立場から
- オキサセフェムの開発
- 第1回長井記念シンポジウム
- 1-オキサセフェム誘導体の合成と抗菌活性
- ヘテロ環を有する二三の天然物の合成
- Oxidation with Nickel Peroxide. IV. The Preparation of Benzoxazoles from Schiff's Bases
- Oxidation with Nickel Peroxide. VII. Oxidation of Aromatic Aldoxime with Nickel Peroxide
- Oxidation with Nickel Peroxide. VI. Oxidation of N-Substituted Hydroxylamine Derivatives with Nickel Peroxide
- Carbapenem and Penem Antibiotics. I. Total Synthesis and Antibacterial Activity of dl-Asparenomycins A, B and C and Related Carbapenem Antibiotics
- ハイドロサィアネーション
- 日本薬学会学術賞受賞夏目充隆氏の業績
- 役員等候補者の選考選出法について(日本薬学会役員選出制度の問題点)
- □オクテット
- 第15回国際化学療法会議